Needham & Company
-
Notable Analyst Rating Changes 07/03: (ZION) (LEAP) (AN) Upgraded; (MJN) (ACCO) (AA) Downgraded
-
Needham & Company Maintains a 'Buy' on Celldex Therapeutics (CLDX); Management Focus Grows on Upcoming Phase 3 Rindopepimut Trial Initiation
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); Five Themes Emerged That We Believe Deserve Increased Attention
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); Pivotal Trial of Rindopepimut in GBM On Track to Start in 2H11
-
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); As CLDX Prepares to Start a Pivotal Trial of Rindopepimut in GBM, CDX-011 in Breast Cancer (Phase 2b) & Other Pipeline Products Adv
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); As the Company Prepares to Start a Pivotal Trial of Rindopepimut in GBM, Other Pipeline Products Continue to Advance
-
Needham & Company reiterates a 'Buy' on Celldex Therapeutics (CLDX); Freezing Weather/Warming Data - Phase 2 Results Presented at the Montreal SNO Meeting Confirm Rindopepimut Potential
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); Internal Phase 2 Programs Continue to Advance
-
2010 ASCO Meeting Preview - Needham & Co Highlights ArQule (ARQL), Celldex (CLDX), Pharmacyclics (PCYC), and Seattle Genetics (SGEN)
-
Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); Lowers PT
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
-
Needham & Co. Upgrades Celldex Therapeutics (CLDX) to Buy
-
Needham & Co Downgrades Celldex Therapeutics (CLDX) to Hold